Restructuring the pipeline, Eli Lilly says a baricitinib comeback in rheumatoid arthritis could take years
Eli Lilly was supposed to mark this year with the launch of a new blockbuster medicine for rheumatoid arthritis — waging a commercial war with some high-profile rivals. Instead, it is now facing a years-long delay in order to mount a new study aimed at resolving the FDA’s safety fears for baricitinib. And its rivals are gaining a big head start in a major market.
In the meantime, Lilly’s Q2 report includes the news that the pharma giant is reorganizing its pipeline, prioritizing 10 drugs in the oncology portfolio while planning to outlicense the rest of the slate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.